Piper Sandler lowered the firm’s price target on Cardiff Oncology (CRDF) to $6 from $10 and keeps an Overweight rating on the shares. The firm notes Cardiff ended 2025 with cash of $58.3M to fund operations into Q1 2027. Piper is pushing out onvansertib approval to 2030, removing value for other cancers and rolling forward its discount period to mid-2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Cardiff Oncology: Promising Onvansertib Data and Solid Cash Runway Support Buy Rating and $10 Price Target
- CRDF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright
- Cardiff Oncology Overhauls Leadership to Advance Onvansertib
- Balancing Leadership Turmoil and Focused Clinical Strategy: Maintaining a Buy on Cardiff Oncology’s Onvansertib Amid Catalyst-Rich Outlook